Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

FDA Oversight By House To Focus On User Fees, Compounding Law

May 05 2014

• By Derrick Gingery

Related Content

Biosimilars: FDA, EMA Developing Common Data Package Guidance

Apr 23 2014

FDASIA Study Mandates Focus On Performance, But Could Slow Reviews

Aug 20 2012

PhRMA, BIO’s PDUFA V Application Tracker Could Inform “Course Corrections”

Jun 26 2013

Teva’s G-CSF Product Clears FDA, Leaving Appeal Of Biosimilar Pathway Uncertain

Sep 03 2012

Related Companies

Teva Pharmaceutical Industries Ltd.

Amgen, Inc.

Additional Topics

United States Regulation Drug Approval Standards Approvals OTC Drugs Consumer BioPharmaceutical Medical Device

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window